Long-Term Disease-Specific Functioning Among Prostate Cancer Survivors and Noncancer Controls in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
Kathryn L. Taylor(Georgetown University Medical Center), Thomas L. Riley(Automation, Information, and Management Systems (United States)), David L. Dawson, Timothy R. Church(University of Minnesota), Kimberly M. Davis(Georgetown University), Sara N. Edmond(Georgetown University), Scott P. Kelly(Pfizer (United States)), Anthony B. Miller(University of Toronto), Jerome Mabie(Information Management Services), Douglas J. Reding(Ascension), George Luta(Georgetown University), Larry R. Muenz(Westat (United States))
Cited by 73
Related Papers
Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood
|New England Journal of Medicine|1993|3.3k
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
The Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal Cancer
|New England Journal of Medicine|2000|1.4k
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
|JNCI Journal of the National Cancer Institute|2012|1.1k
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
|Controlled Clinical Trials|2000|1k